[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581227":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":33,"responsibleParty":51,"collaborators":18,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":18,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study (Adrenaline)","ACTIVE_COMPARATOR","This group will receive the all guidelines-directed recommendations of intervention in STEMI patients.\n\nIntracoronary 10 mcg adrenaline will be given via the guiding catheter in study group after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and\u002For passage of a deflated balloon and\u002For PTCA with a small balloon, and\u002For use of thrombus aspiration and before stenting.",[13],"Drug: Adrenaline",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","This group will receive the standards of care , all guidelines-directed recommendations of intervention in STEMI patients.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Adrenaline","Intracoronary 10 mcg adrenaline will be given via the guiding catheter in study group after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and\u002For passage of a deflated balloon and\u002For PTCA with a small balloon, and\u002For use of thrombus aspiration and before stenting.",[9],[26],"Epinephrine",[28],{"name":29,"role":30,"phone":31,"phoneExt":18,"email":32},"Mostafa Abdallah Khalifa, Master cardiology","CONTACT","+201012988025","mostafaabdallahkhalifa@med.asu.edu.eg",[34],{"facility":35,"status":36,"city":37,"state":18,"zip":18,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Faculty of medicine Ain Shams Univesity","RECRUITING","Cairo","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.24967,30.06263,{"lat":44,"lon":43},[47],{"name":48,"role":30,"phone":49,"phoneExt":18,"email":50},"Khaled Aly, Associate professor","201003593088","Dr.khaled.aly@med.asu.edu.eg",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Mostafa AbdAllah Khalifa","Assistant lecturer of cardiology","100581227","phase-3-the-investigator-administers-intracoronary-adrenaline-via-the-catheter-in-stemi-patients-during-primary-pci-after-flow-restoration-and-before-stenting-and-studies-its-effect-in-prevention-of-no-reflow-100581227",false,"NCT06847568","The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow","Role of Catheter Administered Intracoronary Epinephrine in Prevention of No-Reflow in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients who are 18 years or older\n2. Patients presenting with acute coronary syndrome with ECG criteria diagnostic of STEMI (according to the universal definition of myocardial infarction) within 12 hours from the onset of symptoms and treated by successful primary PCI.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Pregnant females.\n3. Patients refused to give consent.\n4. Patients who had normal coronary angiography.\n5. Patients who had CTO lesions.\n6. Patients who have SCAD.\n7. Patients who developed dissection or mechanical complication during the procedure.\n8. Patients presenting with cardiogenic shock.\n9. Cardiomyopathies\n10. Contraindications to epinephrine as HTN with SBP \\>180 mmHg or DBP\\>110 mmHg, clinically significant arrhythmia (Atrial fibrillation with rapid ventricular rate, ventricular tachycardia, or ventricular fibrillation) prior to PCI, known allergy to epinephrine.","ALL","18 Years",{"count":65,"type":66},1000,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.\n\nThe main question it aims to answer is:\n\nDo prohylcatic intrcoronary adrenaline reduce the incidence of no reflow without increaing risk of arrhythmia in primary PCI?\n\nThe procedure will be performed by expert operators. All patients will receive the guidelines-directed recommendations of intervention of STEMI patients.\n\nStudy group wil receive Intracoronary 10 mcg adrenaline via the guiding catheter after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and\u002For passage of a deflated balloon and\u002For PTCA with a small balloon, and\u002For use of thrombus aspiration and before stenting.\n\nAll steps in the Cath-lab will be described in detail:\n\nThe primary end points will be improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow, and myocardial blush.\n\nSecondary end points will be in-hospital mortality and major adverse cardiac events.",[72,73],"ST Segment Elevation Myocardial Infarction (STEMI)","No Reflow Phenomenon",[75,76,22,77],"STEMI","No-reflow","Prophylaxis","2025-03-07",{"date":80,"type":81},"2025-03-11","ACTUAL",{"date":83,"type":81},"2024-04-01",{"date":85,"type":66},"2026-04-30",{"name":5,"class":6},1]